Abstract: Funding model development for highly specialised therapies

This is an abstract presentation recorded for the Independent Hospital Pricing Authority's (IHPA) Activity Based Funding Conference 2022, which was held virtually from 5 to 6 May 2022.
About this abstract
In July 2019 a block funding arrangement for chimeric antigen receptor (CAR-T) cell therapy was signed for patients with acute lymphyoblastic leukaemia (ALL) or diffuse large B-cell lymphoma (DLBCL). These therapies are classified as highly specialised therapies (HST) under the Addendum to National Health Reform Agreement 2020-2025.
The block funding covers the patient treatment journey across all care settings from acceptance into the program to post transfusion review at twelve months. Unlike other block funding programs, the actual number of patients treated and treatment costs is reconciled by the Administrator to the National Health Funding Pool at the end of each funding period.
In NSW, this treatment is being provided at two adult hospitals and the children’s hospital network, There are fewer paediatric patients indicated for treatment than the adult hospitals, though their patient journeys are more complex.
Presenter
• Ms Susan Dunn, Director, Activity Based Management, Activity Based Management, New South Wales Health,
www.ihpa.gov.au
www.abfconference.com.au